Opioid Settlements Reach Over $37 Billion. Vivera Provides First High-Tech Solution
NEWPORT BEACH, Calif.— Vivera extends an invitation to AbbVie’s Allergan to partner on its high-tech medical device, ZICOH, designed to end addiction, in light of
Vivera Offers Solution Beyond Teva’s Recent $4.35B Opioid Settlement
NEWPORT BEACH, Calif—Amid government settlement discussions with Teva Pharmaceuticals regarding its potential role in the opioid crisis, Vivera invites Teva to join as a partner
Vivera Appoints Dr. Guido Jouret as Interim Chief Technology Officer
NEWPORT BEACH, Calif. — Vivera is pleased to announce the appointment of Guido Jouret, Ph.D., to the Company’s Board of Advisors as Senior Technology Advisor and
Vivera Welcomes Two Veteran Advisors to Its Technology Board
NEWPORT BEACH, Calif. — Vivera is pleased to welcome two Advisors to the Company’s Technology Advisory Board, Mr. Robert Massoudi and Mr. Bryan Hughes. Mr.
Vivera Appoints Dr. Fabio Macciardi as Neurogenetics Scientific Advisor
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals is pleased to welcome Fabio Macciardi, M.D., Ph.D., to its Advisory Board as Neurogenetics Scientific Advisor to the Company’s Biosciences Division.
Vivera Receives 3rd U.S. Patent Allowance for ZICOH Drug Delivery Device
NEWPORT BEACH, Calif.— Vivera is pleased to announce the allowance of its third U.S. patent for ZICOH, the Company’s high-tech, electronic dose-controlled portfolio of drug
Investor Relations and Media Inquiries:
Investor Inquiries:
[email protected]
Media Inquiries:
[email protected]
Forward-looking and cautionary statements:
Statements made on our website may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera’s future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera’s expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera, reference should be made to Vivera’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera’s CSE Listing Statement. The forward-looking information contained on our website is made as of the date of the release of such statement and Vivera does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents on our site.
